Business Wire

Kinaxis Introduces Forward Deployed Engineering to Help Enterprises Turn Decisions into Outcomes

2.6.2026 13:01:00 CEST | Business Wire | Press Release

Share

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today introduced Forward Deployed Engineering (FDE), a new engagement model designed to help enterprises operationalize AI and translate decisions into measurable business outcomes. FDE reflects the broader Kinaxis vision for operational orchestration, an approach that coordinates signals, decisions, actions and learnings across the business fast enough to change outcomes.

The opening keynote at Kinexions, the company’s global customer conference, delivered by CEO Razat Gaurav will be livestreamed globally on June 2 @ 11:30 am EST via LinkedIn Live.

This approach combines a unified data foundation with semantic intelligence that understands the relationships, dependencies, and trade-offs that shape enterprise operations. Together, these capabilities help organizations move beyond isolated decision-making to coordinated execution, connecting data, systems, teams, and actions across the enterprise.

Traditional planning operating models were built around isolated functions, fragmented decisions, and disconnected workflows. Concurrent planning introduced new principles of synchronized, cross-functional decision-making across supply chain planning processes. Operational orchestration extends those principles across enterprise operations, connecting planning, decision-making, and execution both within and beyond the supply chain to create adaptive organizations that continuously align, respond, and improve.

“The challenge companies face is no longer simply making better decisions faster, it’s ensuring those decisions drive real outcomes,” said Razat Gaurav, Chief Executive Officer, Kinaxis. “A supply chain decision only matters when it changes what the business can do. The next shift is ensuring decisions translate into coordinated action across the business. That only happens when AI is grounded in the physics of enterprise operations, understanding the constraints, dependencies, and trade-offs that define how work gets done. With that context, organizations can move from isolated decisions to continuous execution at scale.”

As organizations face increasing volatility, interdependencies, and scale, the challenge is no longer simply making better decisions. It is ensuring those decisions propagate across systems and processes in ways that reflect real-world constraints and deliver meaningful results. Kinaxis believes these same conditions now create the opportunity for AI to generate value, but only when it is grounded in the physics of enterprise operations.

Kinaxis addresses this challenge with composable, extensible capabilities across its platform. Kinaxis is embedding agentic AI directly into operational workflows, enabling new ways of working where teams collaborate with AI to continuously sense, reason, decide, and act within the context of the business. Built on a mature supply chain planning foundation, Kinaxis helps organizations move beyond isolated copilot toward coordinated, scalable execution grounded in their data, constraints, and operating realities.

To support this shift, Kinaxis is expanding beyond traditional software delivery into a model built on interoperable, composable building blocks. These capabilities, spanning data, semantic intelligence, decisioning, AI, and orchestration, can be assembled within Maestro to enhance planning or applied through the FDE motion to support broader operational orchestration across systems, workflows, and enterprise processes.

This shifts the engagement model:

  • From features to outcomes, focusing on business impact rather than predefined requirements
  • From project to product, building solutions that can scale and continuously improve
  • From go-live to ownership, prioritizing sustained adoption and long-term value

Over time, the initial solutions developed through the FDE engagement establish the operational and intelligence foundation for enterprise AI within the customer’s environment. Built on real business context, data, workflows, and decision flows, this foundation enables customers and partners to continuously extend and scale additional agentic capabilities over time.

The result is a more mature operating model where humans and AI agents work seamlessly together across enterprise processes, coordinating decisions, actions, and execution across the flows of materials, resources, and operations that drive the business.

FDE will be available through Kinaxis account teams for selected customer engagements beginning at Kinexions. Kinaxis also announced a customer and partner hackathon focused on accelerating the development of AI-driven solutions aligned to real-world business challenges.

About Kinaxis

Kinaxis is a leader in modern supply chain planning and orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws, including statements relating to the availability, functionality and expected benefits of Kinaxis’ Forward Deployed Engineering model and the Maestro platform, and anticipated customer outcomes. Forward-looking information is based on assumptions and is subject to known and unknown risks and uncertainties that may cause actual results or events to differ materially. Such risks and uncertainties are described in Kinaxis’ filings with Canadian securities regulatory authorities, available on SEDAR+. Forward-looking information is provided as of the date of this press release and, except as required by law, Kinaxis undertakes no obligation to update such information.

Source: Kinaxis Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260602419301/en/

Contacts

Media Relations
Matt Tatham| Kinaxis
mtatham@kinaxis.com - mtatham@kinaxis.co
+1 917-446-72725

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye